Yu J.-L.,Heji Hospital Affiliated to Changzhi Medical School |
Li J.-H.,Tumor Hospital of Shanxi Province |
Chengz R.-G.,Heji Hospital Affiliated to Changzhi Medical School |
Liu J.-C.,First Clinical Hospital of Shanxi Medical School
Asian Pacific Journal of Tropical Medicine | Year: 2014
Objective: To observe the preventive and control effect of matrine on transforming growth factor (TGF-β1) and hepatocyte growth factor (HGF) of liver fibrosis tissue in rats. Methods: A total of 48 SD rats were randomly divided into A, B, C, D groups with 12 in each, group A as the normal control group and groups B, C, D as liver fibrosis models using composite modulus method with carbon tetrachloride (CCL4). Group B was the model group, group C adopted γ-interferon lavage therapy in the second day of modeling, and group D adopted matrine lavage treatment, at 4 and 8 weeks after treatment. Six rats were executed for detection of TGF-β1 and HGF, liver tissue histology and comparison fibrosis degree changes of rat liver tissue between groups. Results: Groups B, C, D showed a more significantly increased TGF-β1 at each time point compared with group A (P<0.05); Group B showed a more significantly increased TGF-β1 than groups C and D at weeks 4 and 8 (P<0.05); group D showed a lowest level of TGF-β1, followed by groups C and B. HGF of group B decreased more significantly than A group at weeks 4 and 8 (P<0.05); HGF of groups C and D was significantly elevated at 4 and 8 weeks than groups A and B (P<0.05), in which the group D showed the highest level of HGF. According to tissue histologic observation, rat liver tissue structure of group A was clear and normal, tissue structure of group B was destroyed with obvious fibrous tissue hyperplasia and fatty change of hepatic cells; groups C and D showed a slighter liver tissue damage, cell necrosis and connective tissue hyperplasia in collect abbacy than group B with a trend of obvious improvement. Conclusions: Matrine can reduce TGF-β1 expression and enhance the activity of HGF, so as to realize the inhibition effect on liver fibrosis in rats. © 2014 Hainan Medical College.
Yuan T.,Tumor Hospital of Shanxi Province |
Wen S.,Tumor Hospital of Shanxi Province |
Dang Z.,Tumor Hospital of Shanxi Province |
Zhang X.,Tumor Hospital of Shanxi Province |
And 2 more authors.
Chinese Journal of Clinical Oncology | Year: 2013
Objective: To determine the effects of Jinlong capsule combined with interventional therapy on the immune functions of primary hepatocellular carcinoma patients. Methods: Sixty randomly selected cases of clinically diagnosed primary hepatocellular carcinoma were divided into the observation group and the control group. Three days after operation, the observation group was given four Jinlong capsules three times a day for 30 days (one treatment). Meanwhile, the control group received interventional therapy after the operation. One to four days following one treatment, peripheral blood specimens were collected from the two groups to determine the cellular immune function indices. Results: The cell numbers (mean) of the peripheral blood components CD3, CD4, NK, SIL-2R, TSGF, and SIL-2R and the CD4/CD8 ratio in the observation group showed no significant difference before and after treatment. In the control group, these indices were significantly different before and after treatment. Conclusion: The Jinlong capsule facilitates the cellular immunity recovery of patients with primary hepatocellular carcinoma after interventional therapy.
Liu Z.,Tumor Hospital of Shanxi Province |
Liu Z.,Xian Jiaotong University |
Sun R.,Xian Jiaotong University |
Lu W.,Tumor Hospital of Shanxi Province |
And 9 more authors.
Medical Oncology | Year: 2012
Perturbations in the apoptotic genes have been implicated in human malignancies. The purpose of the present study was to investigate the polymorphisms of -938C/A, Thr43Ala in anti-apoptotic B-cell lymphoma 2 gene (BCL2) and -248G/A in pro-apoptotic B-cell lymphoma 2-associated X protein gene (BAX) and to explore their role in influencing the susceptibility for development of esophageal cancer. A total of 205 esophageal cancer patients and 224 controls were enrolled in the present study. The genotype and allele distributions of -938C/A, ala43thr in BCL2 and -248G/A in BAX were analyzed in patients and controls, as well as the association of -938C/A genotype with clinical characteristics in patients. We found that homozygous -938A/A genotype of BCL2 gene was significantly associated with risk of developing esophageal cancer (χ2 = 9.269, P = 0.002, OR = 2.585, 95%CI = 1.380-4.842). Association with clinical characteristics showed that the patients with BCL2 -938A/A genotype were more likely to develop into poor differentiation compared with the AC and CC carriers (χ2 = 5.796, P = 0.016, OR = 4.039, 95%CI = 1.200-13.596), and we found smokers were more present in the -938A/A genotype subgroup (χ2 = 5.095, P = 0.024, OR = 2.679, 95%CI = 0.893-8.025). The present study revealed that the -938A/A genotype of BCL2 gene is associated with susceptibility of esophageal cancer. There appeared to be an impact of BCL2 -938A/A genotype on tumor differentiation and smoking. Further studies are needed in a larger population. © 2011 Springer Science+Business Media, LLC.
Zhang J.-P.,Tumor Hospital of Shanxi Province |
Mao G.-H.,Tumor Hospital of Shanxi Province |
Shi T.-L.,Tumor Hospital of Shanxi Province |
Yang X.-L.,Tumor Hospital of Shanxi Province |
And 7 more authors.
Chinese Journal of Cancer Biotherapy | Year: 2011
Objective: To evaluate the safety and therapeutic effect of dentritic cell (DC)-cytokine induced killer cells (CIKs) combined with chemotherapy in treatment of advanced non-small cell lung cancer (NSCLC) patients. Methods: Fifty patients with advanced NSCLC (stage III to IV), who were admitted to Tumor Hospital of Shanxi Province from August 2008 to January 2010, were treated by DC-CIK combined with chemotherapy (docetaxel+cisplatin) and were taken as the combined treatment group; another fifty advanced NSCLC patients who were treated with chemotherapy alone (docetaxel+cisplatin) during the same period were taken as controls. The immune function, therapeutic effect, 1-year survival, life quality, and side effects were compared between the two groups. Furthermore, the safety and therapeutic effects of DC-CIK therapy were observed. Results: DC-CIK cells from NSCLC patients were successfully induced, the ratios of CD3+CD8+ and CD3+CD56+ cells in DC-CIK cells were significantly increased after culture (P<0.05). There were no obvious changes of T cell subsets in the peripheral blood after combined therapy, and the therapy increased IFN-γ level (P<0.05). In the chemotherapy group, the ratios of CD3+CD4+, CD3+CD8+, CD3-CD56+ cells and IL-2, TNF-α levels were significantly decreased after cell culture (P<0.05); and the ratios of CD3+CD8+, CD3+CD56+ cells in DC-CIK was increased (P<0.05). The disease control rate (DCR) of combined therapy group was higher than that in chemotherapy group (78.0% vs 56.0%, P<0.05); the 1-year survival rates of combined therapy group and chemotherapy group were 50% and 44%, respectively, showing no significant difference (P>0.05). The combined therapy group had less side effects(including bone marrow suppression, nausea and vomiting, and peripheral nerve toxicity)compared with the control chemotherapy group (P<0.05). The physical condition and appetite of NSCLC patients in the combined therapy group were better than those in chemotherapy group.Conclusion: Treatment with DC-CIK cells combined with chemotherapy is safe and effective for advanced NSCLC, and it can also improve the remission rate, survival and quality of life of NSCLC patients.